Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
:CMRX
Top Page
Chimerix
(NASDAQ:CMRX)
62Neutral
Positive Factors
Acquisition
The acquisition agreement between Chimerix and Jazz Pharmaceuticals is expected to close in a timely manner, offering a stable financial outlook for Chimerix.
Drug Potential
Dordaviprone, the lead drug in phase III trials, is seen as having the potential to become the standard of care with durable revenues into 2037.
Regulatory Approval
The FDA has accepted Chimerix's NDA with priority review status for dordaviprone, indicating a strong potential for approval.
Negative Factors
Cash Burn
The company's estimated cash burn for the fiscal year is $98 million, suggesting a significant outflow of cash.
Financial Performance
Chimerix reported 4Q24 GAAP EPS of ($0.26) and non-GAAP EPS of ($0.25), both slightly below estimates.
Valuation Concerns
The deal's valuation is lower than the biotech average, suggesting some skepticism about the company's prospects.
Chimerix (CMRX) vs. S&P 500 (SPY)
Market Cap
$797.33M
Dividend YieldN/A
Average Volume (3M)6.45M
Price to Earnings (P/E)―
Beta (1Y)-0.49
Revenue Growth-34.57%
EPS Growth-6.31%
CountryUS
Employees79
SectorHealthcare
Sector Strength71
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.98
Shares Outstanding93,803,850
10 Day Avg. Volume1,548,454
30 Day Avg. Volume6,446,098
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4807.90
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.54Price Target Upside0.47% Upside
Rating ConsensusHold
Number of Analyst Covering5
Chimerix Business Overview & Revenue Model
Company DescriptionChimerix, Inc. (CMRX) is a biopharmaceutical company focused on the development and commercialization of novel antiviral therapeutics. Headquartered in Durham, North Carolina, Chimerix is committed to developing medicines that improve outcomes for patients facing serious diseases. The company's core product includes brincidofovir, an antiviral medication that is in development for various indications, including smallpox and other viral infections. Chimerix aims to address significant unmet medical needs with its innovative drug candidates by leveraging proprietary chemical libraries and expertise in antiviral drug development.
How the Company Makes MoneyChimerix generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by advancing its lead product candidates through clinical trials and seeking regulatory approval for commercial use. Upon approval, revenue is generated through the sale of these drugs to healthcare providers, governments, or other entities. Additionally, Chimerix may engage in licensing agreements, collaborations, or partnerships with other pharmaceutical companies that provide upfront, milestone, and royalty payments, contributing to the company's earnings. Their business model also includes potential government contracts, especially for drugs like brincidofovir, which can be stockpiled for biodefense purposes.
Chimerix Financial Statement Overview
Summary
Chimerix is facing significant financial challenges with negative profitability, declining revenues, and negative cash flow metrics. The income statement reflects negative margins and declining sales. Although the balance sheet shows manageable leverage levels, the company suffers from poor returns on equity. Cash flow issues further emphasize financial instability.Income Statement
Chimerix's income statement shows a challenging financial situation with negative profitability metrics. The TTM (Trailing-Twelve-Months) gross profit margin is negative, indicating more cost than revenue, and the net profit margin is also severely negative. Revenue growth is negative, reflecting declining sales compared to previous periods. Both EBIT and EBITDA margins are negative, pointing to operational inefficiencies.25
Negative
Balance Sheet
The balance sheet displays a relatively strong equity position with a high equity ratio, but this is offset by a negative return on equity due to consistent net losses. The debt-to-equity ratio is low, suggesting manageable leverage levels, but the overall financial health is weakened by sustained losses.40
Negative
Cash Flow
Chimerix's cash flow statement highlights substantial negative free cash flow, with a deteriorating free cash flow growth rate. The operating cash flow to net income ratio is negative, indicating cash outflows are not being effectively managed relative to losses. The free cash flow to net income ratio further emphasizes the cash management challenges.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 159.00K | 324.00K | 33.82M | 1.98M | 5.37M | 12.52M | Gross Profit |
| -21.13M | 324.00K | 33.38M | 1.51M | -30.86M | -25.97M | EBIT |
| -92.83M | -93.06M | -60.39M | -173.40M | -44.52M | 13.54M | EBITDA |
| -92.78M | -92.97M | -60.39M | -90.34M | -44.11M | -44.67M | Net Income Common Stockholders |
| -83.59M | -82.09M | 172.17M | -255.79M | -42.13M | -173.65M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 159.03M | 182.84M | 217.33M | 88.37M | 78.96M | 113.47M | Total Assets |
| 194.04M | 212.77M | 279.34M | 100.54M | 84.72M | 119.38M | Total Debt |
| 1.67M | 1.30M | 2.07M | 16.39M | 2.81M | 196.00K | Net Debt |
| -17.36M | -26.36M | -23.77M | 995.00K | -44.17M | -16.70M | Total Liabilities |
| 19.94M | 19.75M | 22.48M | 32.29M | 11.35M | 9.42M | Stockholders Equity |
| 174.10M | 193.03M | 256.86M | 68.25M | 73.38M | 109.95M |
| Cash Flow | Free Cash Flow | ||||
| -98.64M | -69.18M | -46.94M | -100.14M | -36.10M | -75.34M | Operating Cash Flow |
| -70.45M | -69.09M | -46.87M | -99.93M | -36.04M | -75.18M | Investing Cash Flow |
| 79.42M | 70.60M | 70.04M | -44.09M | 64.71M | 10.63M | Financing Cash Flow |
| 620.00K | 308.00K | -12.72M | 112.43M | 1.41M | 345.00K |
Chimerix Technical Analysis
Positive
8.50
Price Trends
5.83
Positive
3.92
Positive
2.41
Positive
Market Momentum
0.83
Positive
83.50
Negative
64.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMRX, the sentiment is Positive. The current price of 8.5 is above the 20-day moving average (MA) of 8.13, above the 50-day MA of 5.83, and above the 200-day MA of 2.41, indicating a bullish trend. The MACD of 0.83 indicates Positive momentum. The RSI at 83.50 is Negative, neither overbought nor oversold. The STOCH value of 64.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMRX.
Chimerix Risk Analysis
Chimerix disclosed 52 risk factors in its most recent earnings report. Chimerix reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chimerix Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $396.47M | 6.74 | 28.70% | 10.81% | -0.86% | -13.33% | |
67 Neutral | $6.83B | 29.54 | 19.71% | ― | 52.97% | ― | |
62 Neutral | $797.33M | ― | -56.17% | ― | -34.57% | -6.31% | |
52 Neutral | $1.64B | ― | 18.68% | ― | 36.00% | 63.50% | |
51 Neutral | $918.86M | ― | -38.09% | ― | -13.90% | 16.56% | |
49 Neutral | $498.95M | ― | 91.25% | ― | -17.75% | -19.17% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 19.94% | 1.20% |
* Healthcare Sector Average
Performance Comparison
CMRX
Chimerix
8.50
7.45
709.52%
BCRX
BioCryst
7.86
2.81
55.64%
SIGA
SIGA Technologies
5.55
-3.24
-36.86%
SRPT
Sarepta Therapeutics
70.41
-57.99
-45.16%
AKBA
Akebia Therapeutics
1.91
0.28
17.18%
VIR
Vir Biotechnology
6.70
-3.50
-34.31%
Chimerix Earnings Call Summary
Earnings Call Date: Mar 21, 2025 | % Change Since: 0.35% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The call highlighted significant progress in clinical studies and a strong financial position, despite the increased research expenses and net loss. The positive developments in the pipeline and financial management outweigh the challenges.Highlights
Progress in Phase III ACTION Study
Continued enrollment in the global Phase III ACTION study of Dordaviprone, with a positive interim safety review from the Data Monitoring Committee recommending the study continue with no changes.
Nearing Completion of Phase I Dose Escalation Studies
The Phase I dose escalation studies for ONC206 are nearing completion, with the compound showing a well-tolerated profile in adult and pediatric patients.
Financial Position and Cash Runway
Chimerix ended the third quarter with over $152 million in cash and cash equivalents, providing a cash runway extending into the fourth quarter of 2026.
Decreased General and Administrative Expenses
General and administrative expenses decreased significantly to $5.2 million from $9.3 million in the same period in 2023.
Lowlights
Increased Research and Development Expenses
Research and development expenses increased to $19.6 million for the third quarter of 2024, up from $17.4 million in the same period of 2023, primarily due to increased spending on the ACTION study.
Net Loss in the Third Quarter
Chimerix reported a net loss of $22.9 million for the third quarter of 2024, compared to a net loss of $24 million in the third quarter of 2023.
Company Guidance
During the Chimerix third quarter 2024 earnings call, the company provided guidance on several key metrics. The Phase III ACTION study of Dordaviprone is progressing well, with enrollment continuing in 15 countries and a prespecified interim safety review recommending no changes to the study's conduct. This study features two treatment arms, both administering a 625-milligram dose, with one arm administering the dose twice weekly. The company is also nearing the completion of Phase I dose escalation studies for ONC206. Financially, Chimerix reported a net loss of $22.9 million for the quarter, with research and development expenses increasing to $19.6 million, primarily due to the ACTION study. General and administrative expenses decreased significantly to $5.2 million. The company ended the quarter with over $152 million in cash and cash equivalents, providing a cash runway into the fourth quarter of 2026. Additionally, Chimerix is preparing for the potential commercialization of Dordaviprone, with a forecasted global market opportunity of over $750 million, and is planning to file an NDA for provisional approval in Australia by year-end.Chimerix Corporate Events
M&A Transactions
Chimerix Merges with Jazz Pharmaceuticals in $935M Deal
Positive
Mar 5, 2025
On March 4, 2025, Chimerix entered into a merger agreement with Jazz Pharmaceuticals, under which Jazz will acquire Chimerix for $8.55 per share, totaling approximately $935 million. This acquisition, expected to close in the second quarter of 2025, will allow Jazz to expand its oncology portfolio with dordaviprone, a treatment for H3 K27M-mutant diffuse glioma, which has no FDA-approved therapies. The transaction is anticipated to provide Jazz with a near-term commercial opportunity and strengthen its presence in the rare oncology space, while Chimerix shareholders are recommended to tender their shares.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.